Tealwood Asset Management Inc. reduced its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 1.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 37,120 shares of the company’s stock after selling 540 shares during the period. AstraZeneca makes up approximately 1.3% of Tealwood Asset Management Inc.’s investment portfolio, making the stock its 11th biggest holding. Tealwood Asset Management Inc.’s holdings in AstraZeneca were worth $2,892,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. GHP Investment Advisors Inc. acquired a new stake in shares of AstraZeneca during the second quarter worth $26,000. Able Wealth Management LLC acquired a new stake in shares of AstraZeneca during the fourth quarter worth $27,000. Pathway Financial Advisers LLC purchased a new position in shares of AstraZeneca during the first quarter worth $29,000. Hobbs Group Advisors LLC purchased a new position in shares of AstraZeneca during the second quarter worth $35,000. Finally, Pin Oak Investment Advisors Inc. raised its holdings in shares of AstraZeneca by 468.4% during the fourth quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after purchasing an additional 370 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.
AstraZeneca Stock Down 0.3 %
Shares of NASDAQ:AZN traded down $0.26 during trading hours on Tuesday, reaching $76.61. The stock had a trading volume of 776,834 shares, compared to its average volume of 5,160,846. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The firm’s 50 day moving average is $81.59 and its 200-day moving average is $77.60. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The stock has a market capitalization of $237.53 billion, a price-to-earnings ratio of 37.68, a P/E/G ratio of 1.43 and a beta of 0.46.
AstraZeneca Cuts Dividend
The business also recently announced a Semi-Annual dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were issued a $0.49 dividend. This represents a dividend yield of 1.8%. The ex-dividend date was Friday, August 9th. AstraZeneca’s payout ratio is 48.04%.
Analyst Ratings Changes
Several research analysts recently issued reports on the stock. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Barclays raised shares of AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Finally, TD Cowen lifted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $89.75.
View Our Latest Analysis on AZN
AstraZeneca Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
- Five stocks we like better than AstraZeneca
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- Golden Cross Stocks: Pattern, Examples and Charts
- This Is the Entry Into PepsiCo You’ve Been Waiting For
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Dividend-Paying Chip Stocks You Don’t Want to Miss
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.